Current microbiology
July 15, 2025
Gokul Sudhakaran, Shreya Chakraborty, Ashok Kumar et al.
2 citations
Psilocybe species, commonly known as "magic mushrooms", are a group of hallucinogenic fungi known for their psychoactive compounds such as psilocybin, psilocin, baeocystin, and norbaeocystin. These species have been the focus of scientific study due to their potential therapeutic applications, despite their classification as controlled substances in many jurisdictions. This review aims to...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
July 14, 2025
Zoe Plummer, Josh Allen, Justin Brand et al.
4 citations
Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TBI is characterized by neuroinflammation, oxidative stress, impaired neuroplasticity, imbalances in neurotransmission, and cell death - factors that contribute to the development of neurological and psychiatric disorders. Emerging evidence suggests...
Current Topics in Behavioral Neurosciences
July 12, 2025
Wolfgang H. Sommer, Rainer Spanagel
Over a decade after the first edition of "Behavioral Neurobiology of Alcohol Addiction," this chapter revisits the field at a critical juncture, marked by both persistent challenges and emerging opportunities. We reflect on the translational gap that has stalled the development of new treatments for alcohol use disorder (AUD), despite decades of promising preclinical findings. Particular...
ACS Pharmacology & Translational Science
July 11, 2025
Zahira Ziva Cohen, Grace Blest‐hopley
9 citations
The influence of ovarian hormone fluctuations on neurochemistry, cognition, and psychological responses remains insufficiently examined in current psychedelic research and clinical protocols. Traditional practices and case studies underscore the importance of accounting for these factors in investigations of psychedelic effects. This opinion paper explores the critical intersections between...
Journal of Psychopharmacology
July 11, 2025
Aleksander Kwaśny, Patrycja Ciurkowska, Wiesław Jerzy Cubała et al.
6 citations
Background: Although classic psychedelic trials show therapeutic potential, the limited diversity of participants raises concerns about generalizability and safety. Aims: This study assesses the representation of race, ethnicity, and sex in interventional clinical trials of psilocybin and lysergic acid diethylamide (LSD) to evaluate disparities in participant diversity. Methods: We conducted a...
Journal of Psychopharmacology
July 11, 2025
Diana Glenn, Seung Hee Choi, Rick S. Zimmerman
1 citation
Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated anti-addictive properties; however, their impact on smoking behaviors remains under-researched. This review provides a synthesis of the therapeutic potential of these compounds in promoting smoking cessation and reduction. Methods: A systematic...
ACS Omega
July 10, 2025
Taynah Pereira Galdino, Lucas C Oliveira, Mateus A Luz et al.
5 citations
Innovative therapies, such as psilocybin-assisted psychotherapies, hold great promises for treating anxiety, depression, and various other mental health disorders, addressing some of the challenges faced by conventional psychiatric medicine. This study focuses on developing and validating an HPLC-DAD methodology for detecting psilocybin and psilocin in extracts from psychedelic mushrooms...
Nordic Journal of Psychiatry
July 10, 2025
Pernille Kølbæk, Søren Dinesen Østergaard, Jens Larsen
Background Recent studies have suggested that psychedelics such as lysergic acid diethylamide (LSD) and psilocybin might benefit patients with mental illness. This revival calls for revisiting the field’s past experiences with these agents. From 1960 to 1973, many patients were treated with LSD and/or psilocybin at the Department of Psychiatry at Frederiksberg Hospital in Denmark. Here, we...
ACS Chemical Neuroscience
July 9, 2025
Xue Wang, Fan Jun, Cong Lin et al.
4 citations
Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and microbial metabolism. This viewpoint highlights how psychedelics may reshape microbiota and how microbes influence psychedelic efficacy, proposing microbiome-informed strategies─such as probiotics or dietary interventions─to personalize and enhance...
Scientific Reports
July 9, 2025
Stephanie Müller, Federico Cavanna, Laura De la Fuente et al.
3 citations
Serotonergic psychedelics are remarkable for their capacity to induce variable yet reproducible modifications to human consciousness. The acute effects of these compounds include perceptual alterations, predominantly in the visual domain, yet these alterations have been mostly documented only by subjective reports. We used eye-tracking to quantify the effects of low vs. high doses of psilocybin...
ACS Pharmacology & Translational Science
July 8, 2025
Miyuan Zhang, Haiyan Zhai, Liu Yang et al.
1 citation
Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potential therapeutic applications, particularly in the rapid and sustained treatment of depression. However, the potent acute psychedelic effects of psilocybin necessitate a deeper understanding of the neural mechanisms underlying its action. In this study,...
Health policy (Amsterdam, Netherlands)
July 8, 2025
Ramesh Joga, Sravani Yerram, Jayasri Devi Patnam et al.
5 citations
Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions. These substances offer long-term therapeutic benefits, contrasting with the side effects and limitations of current psychiatric medicines. This study examines the legislations and regulatory frameworks for psychedelics in Australia, Canada, The...
npj Aging
July 8, 2025
Kosuke Kato, Yoon-Joo Shin, Cristian Coarfa et al.
11 citations
Abstract Psilocybin, the naturally occurring psychedelic compound produced by hallucinogenic mushrooms, has received attention due to considerable clinical evidence for its therapeutic potential to treat various psychiatric and neurodegenerative indications. However, the underlying molecular mechanisms remain enigmatic, and few studies have explored its systemic impacts. We provide the first...
Molecular Psychiatry
July 7, 2025
Dongsun Park, Gwangho Lee, Won-Gyu Lee et al.
7 citations
Major depressive disorder is a debilitating condition, with many patients unresponsive to conventional monoaminergic antidepressants. Rapid-acting antidepressants such as ketamine and psilocybin offer promising alternatives, relieving symptoms within hours. Ketamine, an NMDA receptor antagonist, and psilocybin, a serotonergic psychedelic primarily targeting 5-HT2A receptors, both enhance...
July 7, 2025
Balázs Szigeti
preprint
Background: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to theoretical concerns of precipitating mania or psychosis. Although psilocybin has demonstrated antidepressant effects when combined with psychotherapy, adverse event reporting is inconsistent, and restrictive eligibility criteria...
bioRxiv (Cold Spring Harbor Laboratory)
July 7, 2025
Akila Ram, Austen B Casey, Robert C. Malenka et al.
2 citations
preprint
Abstract The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some clinical and preclinical data suggest these putative benefits derive from direct analgesic effects. However, this possibility has not been comprehensively tested in preclinical models. Here, we show that psilocybin is not analgesic over a range of doses across multiple pain...
Arts, Culture and Language
July 6, 2025
Yutong Song
Psilocybin, also known as “magic mushrooms,” is naturally found in psychedelic compound from different types of mushrooms. The utility of psilocybin for spiritual and therapeutic purposes has already go through several centuries. Scientific research on these compounds gained traction in the mid-20th century, the increasing interest in the possible therapeutic benefits of psilocybin has led to...
Pharmaceuticals
July 6, 2025
Pauline Braekow, Joachim Neumann, Uwe Kirchhefer et al.
Background/Objectives: Hallucinogenic substances such as psilocybin, psilocin, ergometrine, ergotamine, and lysergic acid diethylamide (LSD) have been demonstrated to enhance the force of contraction (FOC), in part due to the phosphorylation of phospholamban in human atrial preparations via 5-HT4 serotonin receptors and/or H2 histamine receptors. However, whether psilocybin or psilocin acts at...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
July 5, 2025
Hynek Danda, Kristýna Mazochová, Klára Šíchová et al.
1 citation
Baeocystin is a naturally occurring tryptamine-based compound found in various psychoactive mushrooms, including in several species of Psilocybe genus. Due to its structural similarity to psilocybin, which has shown a therapeutic potential in treatment of psychiatric disorders, there is a growing interest in investigating whether baeocystin exhibits comparable effects. This study investigated...
ACS Central Science
July 3, 2025
Mara Johnson-Groh
3 citations
Some scientists think that including secondary compounds from psychedelic mushrooms can make for better drugs. With scarce data, others remain skeptical.